"10.1371_journal.pone.0126847","plos one","2015-05-14T00:00:00Z","Barbara Brunmair; Zsuzsanna Lehner; Karin Stadlbauer; Immanuel Adorjan; Klaus Frobel; Thomas Scherer; Anton Luger; Leonhardt Bauer; Clemens FÃ¼rnsinn","Division of Endocrinology & Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, Austria; 55pharma Drug Discovery & Development AG, Vienna, Austria","Conceived and designed the experiments: LB KF CF IA BB ZL KS. Performed the experiments: BB ZL KS CF IA. Analyzed the data: CF LB IA KF BB ZL KS TS AL. Contributed reagents/materials/analysis tools: IA KF LB AL. Wrote the paper: CF TS.","As in the nature of a drug discovery company, the activities were driven by hopes for commercial reward from patent claims. At present, however, no such intentions are pursued any more with regard to the described compounds. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2015","05","Barbara Brunmair","BB",9,TRUE,7,5,9,2,TRUE,TRUE,FALSE,0,NA,FALSE
